Received Jun 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (ADACEL) | SANOFI PASTEUR | UNK | U8906AA | IM / LA |
4-year-old patient who's supposed to get the 5th dose of dtap, but inadvertently received, adacel with no ae; Initial information received on 26-May-2026 regarding an unsolicited valid non-serious case received from a health care professional. This case involves a 4-year-old female patient who was supposed to receive the 5th dose of DTaP, but inadvertently received DIPHTHERIA, TETANUS AND ACELLULAR PERTUSSIS VACCINE (ADACEL) with no ae (adverse event). The patient's past medical history, past drugs, vaccination(s), family history, and concomitant medications were not provided. Concomitant medication(s) included [Measles vaccine, Mumps vaccine, Rubella vaccine (MMR), ADACEL PRE-FILLED SYRINGE (ADACEL PRE-FILLED SYRINGE), Diphtheria vaccine toxoid, Pertussis vaccine acellular, Tetanus vaccine toxoid (Tdap)]. On 22-May-2026, the patient received a 0.5 mL once dose of DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL] Suspension for injection (batch: U8906AA, expiration date: 30-May-2028) via intramuscular route left deltoid strength: standard in an unknown administration site for Immunisation, A certified medical assistant (CMA) called to get clinical recommendations for a 4-year-old patient who was supposed to receive the 5th dose of DTaP (Diphtheria-Tetanus-acellular Pertussis), but inadvertently received ADACEL (Tdap) with no ae (adverse event) [(Wrong product administered, onset: 22-May-2026 and latency: same day)]. Action taken: Not applicable This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Comments: NONE
Mmr; Tdap